UK CRO BioPharmaSpec eyes growth in India and Asia-Pacific

By Gareth Macdonald contact

- Last updated on GMT

UK CRO BioPharmaSpec eyes growth in India and Asia-Pacific

Related tags: Contract research organization, Asia

BioPharmaSpec has set up business development teams for the Indian and Asia-Pacific markets and predicted increased demand for biosimilar characterisation services.

The UK-headquartered contract research organisation (CRO) announced the move this week, explaining that the aim is to expand its customer base and deepen established relationships with companies in Asia.

CEO Andrew Reason said: “We are an international CRO, performing a comprehensive range of characterization services from fully-equipped, modern laboratories in both the UK and USA. Asia is an important aspect of our expansion plans​.”

He also suggested companies developing biosimilars in Asia would welcome the chance to work with an experienced CRO.

The structural characterization of biopharmaceutical products is a broad and complicated process and a wide variety of techniques are involved in providing full characterization information.

For these reasons, I believe that our industry values proven technical expertise and product experience when selecting a CRO partner, especially when important decisions relating to comparability or biosimilarity are to be made​.”

News of the expansion plan comes just under a year after BioPharmaSpec opened a new characterization services laboratory in the US.

Singapore lab mulled

The facility in Malvern, Pennsylvania, in the greater Philadelphia area, provides de novo​ Protein Sequencing, Peptide Mapping, Disulfide Bridge and Carbohydrate Analysis.

Lindsay Farrell, head of business development, told us: “We are currently assessing the requirement for a lab in the region and are in particular exploring an option we have in Singapore.

The expansion of our business development capabilities, in order to build upon the client base we have already established in the region, is part of this process and we look forward to using our technical expertise and regulatory experience to help accelerate our Asian clients’ products through the development pipeline​.”

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars